InfinimmuneImmunotherapy
Infinimmune develops engineered T cell immunotherapies to treat cancer and autoimmune diseases.
$75MSeries A
Investor undisclosed
A $75M Series A for cell therapy in 2026 signals that engineered T cell platforms are still attracting serious capital despite the category's clinical setbacks—likely because this round is probably funding late-stage manufacturing scale and Phase 2 data generation, not early discovery. If you're building adjacent biotech infrastructure (manufacturing, cell sourcing, data analytics for patient selection), this validates that the bottleneck isn't investor appetite but execution risk on efficacy and cost.